<b>Background:</b> Antiangiogenic therapy with anti-vascular endothelial growth factor (VEGF) is commonly used to treat diabetic macular edema (DME), which can reduce edema, improve vision, and prevent further visual loss. This evidence concerns the gene VEGFA and diabetic macular edema.